WRAL Tech Wire

 Liquidia's preclinical studies offer insight into new company's plans

This week Liquidia presented data from two preclinical studies at the annual meeting of the Association for Research in Vision and Ophtalmology, studies that offer a peek at ophtalmic applications Liquidia has been researching.

 Nanotech firm Liquidia eyes ophthalmology opportunity with new company

Nanotechnology company Liquidia plans to spin off a separate company. Read more about the therapeutic and financial opportunities Liquidia sees in eye drugs.

 Liquidia mulls spinning off two nanotechnology companies

CED Life Science Conference 2013: Nanotechnology company Liquidia is considering spinning its research off into one, perhaps even two companies to pursue different targets utilizing its proprietary nanoparticle technology.

 Liquidia to pursue new pneumonia vaccine

The Research Triangle Park-based firm is working with PATH to conduct preclinical studies on a "next generation" pneumococcal vaccine that could be more effective than existing vaccines and more efficient to produce.

 Medical device startup lands former Liquidia COO as marketing exec

Todd Pope, the CEO at venture-backed TransEnterix, hires Luke Roush as vice president for marketing. Pope is a former Liquidia CEO.

 Liquidia Technologies names chief medical officer